A Study Evaluating the Effect of Etoricoxib & Indomethacin in

Updated 06/21/2024

Status Completed

Clinical Trial Summary

A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00142558
Study type	Interventional
Source	Organon and Co
Contact
Status	Completed
Phase	Phase 4
Start date	January 1, 2005
Completion date	May 1, 2005

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT02674776` - Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout	Phase 3
	Not yet recruiting	`NCT05925166` - Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout	N/A
	Completed	`NCT00798369` - Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients	Phase 2
	Active, not recruiting	`NCT05328531` - Clinical Study of Genakumab for Injection in Patients With Acute Gout	Phase 1/Phase 2
	Completed	`NCT01080131` - Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.	Phase 3
	Recruiting	`NCT05936268` - Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare	Phase 2
	Not yet recruiting	`NCT05936281` - Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy	Phase 2
	Recruiting	`NCT05588908` - A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout	Phase 1/Phase 2
	Recruiting	`NCT05698680` - Prednisolone Versus Colchicine for Acute Gout in Primary Care	Phase 4
	Recruiting	`NCT05983445` - Safety & Efficacy of Genakumab in Patients With Frequent Flares	Phase 3
	Not yet recruiting	`NCT06169891` - A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout	Phase 3
	Completed	`NCT01029652` - Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study	Phase 3
	Withdrawn	`NCT00997581` - Apremilast Therapy for Acute Gouty Arthritis	Phase 2